Forbius

Forbius is a clinical stage protein engineering company that designs, develops & commercializes biotherapeutics for the treatment of cancer & fibrotic diseases.

[Forbius @Forbius_]

Bristol Myers Squibb ($BMY) to Acquire #Forbius #TGF-beta Program
#oncology #fibrosis #biotech
https://t.co/aRhG7KdQyW

[Forbius @Forbius_]

Forbius reports initial results from #AVID200 Phase 1 systemic sclerosis trial #EULAR2020 #biotech #pharmaceuticals #scleroderma #Austin #Montreal

https://t.co/5nht8wYQ2J

[Forbius @Forbius_]

Forbius to report first clinical data in #fibrosis with first-in-class selective #TGFbeta inhibitor at #EULAR2020 #biotech #pharmaceuticals #scleroderma #Austin #Montreal

https://t.co/hlBk84ZhOq

[Forbius @Forbius_]

Forbius to report Phase 1 clinical #oncology data with selective #TGF-beta inhibitor #AVID200 at #ASCO2020
#biotech #pharmaceuticals #IO #Austin #Montreal

https://t.co/vOIKCS0Zyj

[Forbius @Forbius_]

Forbius to present at the @SoleburyTrout Virtual Investor Conference on April 2, 2020 at 2:30PM ET. An interactive Q&A with participants will be included.

Click here to join: https://t.co/K1b71JlAMg

#Forbius #Biotech #Pharmaceuticals #Austin #Montreal

[Forbius @Forbius_]

Forbius to present at Jefferies 2019 London Healthcare Conference
#Forbius #Jefferies2019 #Healthcare #Conference #biotech #pharmaceuticals #Austin #Montreal #London

https://t.co/rMtlbiyCbJ

[Forbius @Forbius_]

Forbius today reported Phase 1 #oncology data with #First-in-Class #TGFbeta inhibitor #AVID200 in a late-breaking poster presentation at #SITC2019.

#SITCancer #IO #immunotherapy #cancer #pharmaceuticals #biotech #Austin #Montreal

[Forbius @Forbius_]

Forbius to report #AVID200 Phase 1a #oncology clinical data at #SITC2019 #SITCancer #biotech #pharmaceuticals #IO #immunotherapy #Austin #Montreal

[Forbius @Forbius_]

@Forbius_ Completes Enrollment into Phase 1a #immuneoncology Trial of #AVID200, First-in-Class #TGFbeta 1 & 3 Inhibitor; Closes #SeriesC #Financing.

#biotech #pharmaceuticals #IO #Austin #Montreal

[Forbius @Forbius_]

Meet us @World_ADC in San Diego! Our CSO, Maureen O'Connor, will give an invited talk on #AVID100 - our novel #EGFR #ADC in Phase 2 development in #HNSCC, #TNBC and #NSCLC. #biotech #pharmaceuticals #Austin #Montreal #SanDiego #worldADC

[Forbius @Forbius_]

https://t.co/UCItQXThs7

[Forbius @Forbius_]

@Forbius_ Announces AVID200, a First-in-Class TGF-beta 1 & 3 Selective Inhibitor, to be Featured at
ESMO and CICON 2019: https://t.co/R2lVzxb7lO

#Forbius #ESMO #CICON #Austin #Montreal #Paris #Barcelona #AVID200

[Forbius @Forbius_]

https://t.co/h5KYA0NhWv

[CNRC @CNRC_NRC]

#LSV? Il n’y a pas de traitement efficace pour la plupart des maladies fibreuses. Nous travaillons avec @Forbius_ pour rectifier la situation! https://t.co/MQP42I41q3 #SantéCNRC #Forbius #AVID200 #EssaisCliniques #TGFBeta #biotech #SemaineInnovationCanadienne

[NRC Canada @NRC_CNRC]

#DYK? There are no effective treatments for most fibrotic diseases. We’re working with @Forbius_ to change that! https://t.co/DufMbHOeRZ #NRCHealth #Forbius #AVID200 #ClinicalTrials #TGFBeta #BioTech #CanadianInnovationWeek

[Forbius @Forbius_]

@Forbius_ to Present at @Jefferies 2019 Healthcare Conference: https://t.co/PMRbyJ2YLP

#Forbius #Jefferies2019 #Healthcare #Conference #Austin #Montreal #NYC

[CNRC @CNRC_NRC]

La #collaboration est une composante essentielle de l’#innovation. C’est pourquoi nous nous associons à des entreprises canadiennes comme @Forbius_ pour créer les #biothérapies de demain! https://t.co/z1uvFNPPEy #SantéCNRC #SemaineInnovationCanadienne

[NRC Canada @NRC_CNRC]

#Collaboration is the soul of #innovation – that’s why we’re partnering with Canadian companies like @Forbius_ to deliver the #Biotherapeutics of tomorrow! https://t.co/Juo39vZPSp #NRCHealth #CanadianInnovationWeek

[Forbius @Forbius_]

https://t.co/wCjGc9Aoh6

[Forbius @Forbius_]

Forbius' AVID100, a Novel Anti-EGFR ADC, Cleared by Health Canada to Commence Phase 2 Clinical Trials in EGFR-overexpressing SCCHN, NSCLC and TNBC: https://t.co/kBreqAAV3p

#Forbius #ClinicalTrial #AVID100 #HealthCanada #Austin #Texas #Montreal #Quebec #Phase2 #News